Hoth Therapeutics (HOTH) denied market rumors on Wednesday regarding plans to raise fresh capital.
The company said it has no plans for a public or private offering at this time. It also said it had over $10 million in cash and no debt -- enough funding to execute its strategic initiatives and advance its pipeline.
The company added that enrollment in the clinical trial of its lead therapeutic candidate HT-001 to treat rash and skin disorders associated with cancer therapy is "proceeding as planned."
Hoth Therapeutics shares were up more than 8% in recent trading.
Price: 2.48, Change: +0.20, Percent Change: +8.55
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。